Becton Dickinson Resumes U.S. Shipments of ChloraPrep

Dow Jones05-29

By Dean Seal

Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month.

The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals.

Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility.

The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 29, 2026 09:21 ET (13:21 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639620010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639620010","market":"other","top_or_hot":-1,"title":"Becton Dickinson Resumes U.S. Shipments of ChloraPrep","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n</p>\n<p>\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n</p>\n<p>\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n</p>\n<p>\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 09:21 ET (13:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Becton Dickinson Resumes U.S. Shipments of ChloraPrep</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBecton Dickinson Resumes U.S. Shipments of ChloraPrep\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-29 21:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n</p>\n<p>\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n</p>\n<p>\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n</p>\n<p>\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 09:21 ET (13:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0072461881.USD","symbol_name":"BGF US BASIC VALUE \"A2\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639620010","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639620010","pubTimestamp":1780060860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month.The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals.Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility.The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4588":"碎股","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BDX":"碧迪医疗","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BK4585":"ETF&股票定投概念","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","BK4082":"医疗保健设备","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4504":"桥水持仓","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H"},"translate_title":"Becton Dickinson恢复ChloraPrep在美国的发货","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Becton Dickinson has resumed shipments of its antiseptic skin preparation agent ChloraPrep in the U.S. after placing a voluntary hold on it earlier this month. \n\n\n  The medical-technology company said it has done additional final release testing on ChloraPrep that has been acceptable, and there have been no patient safety signals. \n\n\n  Shipments had been placed on hold after Becton Dickinson received a warning letter from the Federal Drug Administration tied to an October inspection of the company's El Paso manufacturing facility. \n\n\n  The letter cited deficiencies in the company's compliance with manufacturing standards, including inadequate investigation of complaints, insufficient laboratory controls and shortcomings in equipment clearing, among others, according to a regulatory filing. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 09:21 ET (13:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639620010","isCrawlerRequest":true}